Humoral immune response to polyvalent pneumococcal vaccine in healthy participants receiving efgartigimod: a randomized, open-label, placebo-controlled, parallel-group phase 1 trial

Antoine E. Azar, John W. Sleasman, Sophie Steeland, Fien M. Verhamme, Kevin L. Winthrop

Open source

DOI
10.3389/fimmu.2026.1799480
Published
2026-05-07
Container
Frontiers in Immunology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1799480,
  title = {Humoral immune response to polyvalent pneumococcal vaccine in healthy participants receiving efgartigimod: a randomized, open-label, placebo-controlled, parallel-group phase 1 trial},
  author = {Antoine E. Azar and John W. Sleasman and Sophie Steeland and Fien M. Verhamme and Kevin L. Winthrop},
  year = {2026},
  journal = {Frontiers in Immunology},
  doi = {10.3389/fimmu.2026.1799480},
  url = {https://doi.org/10.3389/fimmu.2026.1799480}
}

RIS

TY  - JOUR
TI  - Humoral immune response to polyvalent pneumococcal vaccine in healthy participants receiving efgartigimod: a randomized, open-label, placebo-controlled, parallel-group phase 1 trial
AU  - Antoine E. Azar
AU  - John W. Sleasman
AU  - Sophie Steeland
AU  - Fien M. Verhamme
AU  - Kevin L. Winthrop
PY  - 2026
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1799480
UR  - https://doi.org/10.3389/fimmu.2026.1799480
ER  - 

APA

Azar, A. E., Sleasman, J. W., Steeland, S., Verhamme, F. M., & Winthrop, K. L. (2026). Humoral immune response to polyvalent pneumococcal vaccine in healthy participants receiving efgartigimod: a randomized, open-label, placebo-controlled, parallel-group phase 1 trial. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1799480

Source records